Karyopharm Therapeutics Inc. KPTI
Karyopharm Therapeutics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -62.1% | -82.2% | -88.7% | -90.5% | -46.8% | -159.0% | -462.9% | -593.0% | -8133.2% | -71903.9% |
| Net margin | -134.2% | -52.6% | -98.0% | -105.2% | -59.1% | -181.6% | -488.1% | -588.1% | -8036.4% | -71153.9% |
| FCF margin | -51.6% | -87.9% | -63.5% | -95.3% | -51.2% | -148.4% | -467.1% | -532.3% | -4596.8% | -54844.8% |
| Return on assets | -180.8% | -46.5% | -59.5% | -46.1% | -40.6% | -62.7% | -67.7% | -52.3% | -71.5% | -60.7% |
| Return on equity | 66.9% | 41.1% | 105.1% | 992.4% | 155.7% | -388.3% | -401.0% | -97.4% | -99.6% | -67.5% |
| Debt / equity | — | — | — | — | -2.12× | — | — | — | — | — |
| Current ratio | 1.12 | 1.70 | 3.37 | 5.31 | 3.74 | 4.59 | 6.01 | 7.13 | 3.00 | 7.99 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.